Not like there was ever much value assigned to NS5A program; believe it was only at research stage, earlier than the nuke program at pre-clinical stage. Bulk of Medivir valuation in near-term going to be tied directly to simeprevir's prospects.
There's plenty of NS5A inhibitors in clinical testing that lack pan-genotypic activity. These drugs have limited value going forward yet most American developers continue to feed the zebra. Medivir deserves credit for coming out and announcing their priorities.
Market Data 
Markets 
AI
